236 related articles for article (PubMed ID: 26687450)
1. Overexpression of NAD(P)H:quinone oxidoreductase 1 (NQO1) and genomic gain of the NQO1 locus modulates breast cancer cell sensitivity to quinones.
Glorieux C; Sandoval JM; Dejeans N; Ameye G; Poirel HA; Verrax J; Calderon PB
Life Sci; 2016 Jan; 145():57-65. PubMed ID: 26687450
[TBL] [Abstract][Full Text] [Related]
2. Cancer Cell Sensitivity to Redox-Cycling Quinones is Influenced by NAD(P)H: Quinone Oxidoreductase 1 Polymorphism.
Glorieux C; Buc Calderon P
Antioxidants (Basel); 2019 Sep; 8(9):. PubMed ID: 31480790
[TBL] [Abstract][Full Text] [Related]
3. NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells.
Singh S; Zahid M; Saeed M; Gaikwad NW; Meza JL; Cavalieri EL; Rogan EG; Chakravarti D
J Steroid Biochem Mol Biol; 2009 Oct; 117(1-3):56-66. PubMed ID: 19628038
[TBL] [Abstract][Full Text] [Related]
4. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
Siegel D; Yan C; Ross D
Biochem Pharmacol; 2012 Apr; 83(8):1033-40. PubMed ID: 22209713
[TBL] [Abstract][Full Text] [Related]
5. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.
Fagerholm R; Hofstetter B; Tommiska J; Aaltonen K; Vrtel R; Syrjäkoski K; Kallioniemi A; Kilpivaara O; Mannermaa A; Kosma VM; Uusitupa M; Eskelinen M; Kataja V; Aittomäki K; von Smitten K; Heikkilä P; Lukas J; Holli K; Bartkova J; Blomqvist C; Bartek J; Nevanlinna H
Nat Genet; 2008 Jul; 40(7):844-53. PubMed ID: 18511948
[TBL] [Abstract][Full Text] [Related]
6. NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.
Zhang K; Chen D; Ma K; Wu X; Hao H; Jiang S
J Med Chem; 2018 Aug; 61(16):6983-7003. PubMed ID: 29712428
[TBL] [Abstract][Full Text] [Related]
7. NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells.
Gray JP; Karandrea S; Burgos DZ; Jaiswal AA; Heart EA
Toxicol Lett; 2016 Nov; 262():1-11. PubMed ID: 27558805
[TBL] [Abstract][Full Text] [Related]
8. Synergistic enhancement of antitumor effect of β-Lapachone by photodynamic induction of quinone oxidoreductase (NQO1).
Lamberti MJ; Vittar NB; da Silva Fde C; Ferreira VF; Rivarola VA
Phytomedicine; 2013 Aug; 20(11):1007-12. PubMed ID: 23746950
[TBL] [Abstract][Full Text] [Related]
9. Efficient NQO1 substrates are potent and selective anticancer agents.
Parkinson EI; Bair JS; Cismesia M; Hergenrother PJ
ACS Chem Biol; 2013 Oct; 8(10):2173-83. PubMed ID: 23937670
[TBL] [Abstract][Full Text] [Related]
10. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.
Colucci MA; Moody CJ; Couch GD
Org Biomol Chem; 2008 Feb; 6(4):637-56. PubMed ID: 18264564
[TBL] [Abstract][Full Text] [Related]
11. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
12. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
Beall HD; Winski S; Swann E; Hudnott AR; Cotterill AS; O'Sullivan N; Green SJ; Bien R; Siegel D; Ross D; Moody CJ
J Med Chem; 1998 Nov; 41(24):4755-66. PubMed ID: 9822546
[TBL] [Abstract][Full Text] [Related]
13. DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma.
Cabello CM; Lamore SD; Bair WB; Davis AL; Azimian SM; Wondrak GT
Free Radic Res; 2011 Mar; 45(3):276-92. PubMed ID: 21034357
[TBL] [Abstract][Full Text] [Related]
14. 2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
Bian J; Deng B; Xu L; Xu X; Wang N; Hu T; Yao Z; Du J; Yang L; Lei Y; Li X; Sun H; Zhang X; You Q
Eur J Med Chem; 2014 Jul; 82():56-67. PubMed ID: 24874653
[TBL] [Abstract][Full Text] [Related]
15. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
16. Arsenite pretreatment enhances the cytotoxicity of mitomycin C in human cancer cell lines via increased NAD(P)H quinone oxidoreductase 1 expression.
Lin YL; Ho IC; Su PF; Lee TC
Toxicol Appl Pharmacol; 2006 Aug; 214(3):309-17. PubMed ID: 16494910
[TBL] [Abstract][Full Text] [Related]
17. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
Winski SL; Swann E; Hargreaves RH; Dehn DL; Butler J; Moody CJ; Ross D
Biochem Pharmacol; 2001 Jun; 61(12):1509-16. PubMed ID: 11377380
[TBL] [Abstract][Full Text] [Related]
18. Increased tumor necrosis factor-alpha sensitivity of MCF-7 cells transfected with NAD(P)H:quinone reductase.
Siemankowski LM; Morreale J; Butts BD; Briehl MM
Cancer Res; 2000 Jul; 60(13):3638-44. PubMed ID: 10910079
[TBL] [Abstract][Full Text] [Related]
19. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
Han Y; Shen H; Carr BI; Wipf P; Lazo JS; Pan SS
J Pharmacol Exp Ther; 2004 Apr; 309(1):64-70. PubMed ID: 14718602
[TBL] [Abstract][Full Text] [Related]
20. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity.
Traver RD; Horikoshi T; Danenberg KD; Stadlbauer TH; Danenberg PV; Ross D; Gibson NW
Cancer Res; 1992 Feb; 52(4):797-802. PubMed ID: 1737339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
